E.E.S., Eryped

Treats infections caused by susceptible strains of the designated organisms in the…. NDA 50207, held by Carnegie. Erythromycin Ethylsuccinate.

As of Nov 13, 2026, NDA 50207 (E.E.S., Eryped), held by Carnegie, was first approved by FDA on Apr 2, 1965, with 18 approved supplements and 0 published complete response letters.

First approved: Apr 2, 1965
Supplements approved: 18
Complete response letters: 0

What It's For

From the FDA-approved label (Indications and Usage)

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Full prescribing information on DailyMed ↗

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 19 submissions below

Date	Submission	Status	Documents
Apr 2, 1965	Original application	Approved	None posted

Products

3 strengths and forms

Product	Active ingredient	Marketing
E.E.S.EQ 200MG BASE/5ML · granule;oral	Erythromycin Ethylsuccinate	RxReference drug
ErypedEQ 400MG BASE/5ML · granule;oral	Erythromycin Ethylsuccinate	RxReference drug
ErypedEQ 200MG BASE/5ML · granule;oral	Erythromycin Ethylsuccinate	RxReference drug

All 19 submissions, including labeling and manufacturing supplements

Date	Submission	Status	Documents
Apr 23, 2018	Supplement 74Labeling · Standard review	Approved	Label Letter
Aug 17, 2017	Supplement 73Labeling · Standard review	Approved	Label Letter
Feb 2, 2012	Supplement 71Labeling · Standard review	Approved	Letter Label
Jan 26, 2011	Supplement 64Labeling · Standard review	Approved	Letter Label
Nov 4, 2010	Supplement 67Labeling · Standard review	Approved	Letter
Dec 10, 2008	Supplement 68Labeling · Standard review	Approved	Label Letter
May 22, 2008	Supplement 66Labeling · Standard review	Approved	Letter
Jan 5, 2008	Supplement 65Labeling · Standard review	Approved	Letter Label
Aug 10, 2006	Supplement 58Labeling · Standard review	Approved	Letter Label
Mar 12, 2004	Supplement 61Labeling · Standard review	Approved	Letter
Apr 25, 2002	Supplement 57Labeling · Standard review	Approved	Letter
Feb 4, 2000	Supplement 55Labeling · Standard review	Approved	Review
Feb 4, 2000	Supplement 54Labeling · Standard review	Approved	Review
Nov 24, 1999	Supplement 56Manufacturing	Approved	None posted
May 9, 1997	Supplement 53Manufacturing	Approved	None posted
Apr 29, 1997	Supplement 52Manufacturing	Approved	None posted
Apr 14, 1997	Supplement 51Labeling	Approved	None posted
Apr 14, 1997	Supplement 50Labeling	Approved	None posted
Apr 2, 1965	Original application	Approved	None posted

Identifiers

Application: NDA 50207
Drugs@FDA: Overview at FDA
Company: Carnegie

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters